Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7305effc496dec13622f0c922f5578db |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G69-48 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G69-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C08G69-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-34 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08G69-10 |
filingDate |
2018-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1dd95c1e7b709644ae071a4f74ee094 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_76a1a308bcae5c228f17713d2c97af7a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_acf5f069b132ad712b5520f8d2cc4a28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f32ba3fdd7f03b0f15a39b4018f4a7a3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8c84bafbe5fd28db59f6266b0fab0a77 |
publicationDate |
2020-10-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
MX-2020005916-A |
titleOfInvention |
COMPOSITIONS IN THE FORM OF AN AQUEOUS INJECTABLE SOLUTION COMPRISING AMYLIN, AN AMYLIN RECEPTOR AGONIST OR AN AMYLIN ANALOGUE, AND A COPOLYAMINO ACID. |
abstract |
The invention relates to a composition in the form of an injectable aqueous solution, for which the pH is between 6.0 and 8.0, comprising at least: a) amylin, an amylin receptor agonist or an amylin analogue; b) a copolyamino acid with carboxylate charges and hydrophobic radicals Hy, said copolyamino acid is constituted by glutamic or aspartic units and said hydrophobic radicals -Hy are selected according to formula X as defined below: C9 (see formula) Formula X characterized because the composition does not include basal insulin for which the IP isoelectric point is between 5.8 and 8.5. It also refers to a composition characterized in that it also comprises a prandial insulin. |
priorityDate |
2017-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |